Small Cell Carcinoma of the Esophagus: A Nationwide Analysis of Treatment and Outcome at Patient Level in Locoregional Disease. (June 2019)

• Record Type: Journal Article
• Authors: Jeene, Paul M.; Geijsen, Elisabeth D.; Muijs, Christina T.; Rozema, Tom; Aleman, Berthe M.P.; Muller, Karin; Baas, Jara M.; Nuyttens, Joost J.; Wouterse, Sanne; Braam, Pètra M.; Oppedijk, Vera; Ceha, Heleen M.; Cnossen, Jeltsje; Spruit, Patty; Bongers, Eva M.; Berbée, Maaike; Mook, Stella; Hulshof, Maarten C.C.M.
• Is Part Of: American journal of clinical oncology. Volume 42:Number 6(2019)
• Publication Date: 2019-06
• Subjects: small cell carcinoma -- esophagus -- chemotherapy -- radiotherapy -- chemoradiotherapy -- outcome -- survival; Cancer -- Treatment -- Periodicals; Oncology -- Periodicals; Tumors -- Periodicals; 616.994005
• DOI: 10.1097/COC.0000000000000546
• Languages: English
• ISSNs: 0277-3732

Abstract

Abstract : Background and Purpose: Small cell carcinoma of the esophagus (SCEC) is a rare subtype of esophageal cancer for which optimal treatment is unknown. We analyzed the impact of treatment factors on outcome in patients with nonmetastasized SCEC. Methods: Patients with a histologically confirmed SCEC without distant metastases were analyzed in a nationwide multicenter retrospective cohort. All patients received radiotherapy as part of curative treatment between January 2000 and December 2014. Details on treatment and outcome were retrieved from individual charts. Cox regression analysis was used to determine prognostic factors for survival. Results: Fifty-eight patients were analyzed. Median survival was 16 months (95% confidence interval, 11-21 mo). Infield recurrences occurred in 25%, distant metastases in 45%, and brain metastases in 12%. In total, 63% of patients developed a recurrence. Most recurrences (67%) occurred within 1 year. In univariable analyses an increased number of chemotherapy cycles (>3) and lower radiotherapy doses (<45 Gy) were associated with improved survival. T-stage, N-stage, treatment period, type of chemotherapy, prophylactic cranial irradiation, and age were not associated with survival. In multivariable analyses, only the number of chemotherapy cycles was associated with better survival (hazard ratio, 0.78; P =0.006). Conclusions: SCEC recurs frequently at distant sites after definitive chemoradiotherapy and usually within 1 year after curative treatment. With a dose of 45 to 50 Gy, infield recurrence rate was low. We found a relationship between number of received chemotherapy cycles and survival with best results obtained after at least 4 cycles of chemotherapy. Abstract : Supplemental Digital Content is available in the text.